Jyothy Labs Ltd. announces a capital-allocation move

The ₹147 Cr buyback would reduce Jyothy Labs’ Q2 FY27 cash balance by approximately 17.4%, leaving an estimated ₹699 Cr of cash and net cash, assuming the buyback is funded entirely from existing cash and no debt is raised. The board-approved buyback is at ₹215 per share and promoters are not participating. ^[1]

Cash and net-cash impact

• Cash and cash equivalents before buyback: approximately ₹846 Cr ^[1]
• Buyback cash outflow: ₹147 Cr ^[1]
• Derived cash after buyback: approximately ₹699 Cr
• Cash reduction: 17.4%, derived as ₹147 Cr ÷ ₹846 Cr
• Net cash before buyback: approximately ₹846 Cr, since reported debt was zero ^[1]
• Derived net cash after buyback: approximately ₹699 Cr, assuming debt remains zero

The residual cash would still cover roughly 4.8 times the buyback outflow, so the transaction represents a meaningful but not balance-sheet-stressing use of liquidity.

Liquidity-ratio effect

The buyback would mechanically reduce current assets and cash-based liquidity by ₹147 Cr, while current liabilities would be unchanged immediately:

• Cash ratio: falls by the same ₹147 Cr reduction in cash divided by current liabilities.
• Current ratio: also declines because current assets fall, although the exact post-buyback ratio requires the Q2 FY27 current-liability figure.
• Debt-to-equity: should remain broadly unchanged at zero debt, assuming no borrowing is used to fund the buyback.
• Net-cash-to-equity: declines, but the company remains net-cash positive.

For reference only, FY25 current assets were ₹1,411.4 Cr and current liabilities were ₹510.77 Cr, implying a historical current ratio of approximately 2.76x; these are not the latest quarterly figures and should not be treated as the Q2 FY27 post-buyback ratio. ^{[2] [3]}

Assessment: the buyback consumes around one-sixth of the latest reported cash balance, but leaves a substantial cash surplus and no reported debt. The main analytical limitation is that the Q2 FY27 current-assets and current-liabilities figures needed to calculate the exact post-buyback current ratio and cash ratio could not be confirmed from the cited sources.

Promoters and the promoter group, who are the persons in control, stated that they will not participate in the tender-offer buyback. Their shares will therefore be excluded when calculating the entitlement ratio. ^{[4] [5]}

• Proposed buyback: up to 68,37,210 shares, equivalent to 1.86% of the total paid-up equity share capital as of March 31, 2026. ^[6]
• Capital-return comparison: the announcement confirms that Jyothy Labs had not undertaken any buyback during the one year preceding the November 4, 2026 board meeting. ^[4]
• Limitation: a like-for-like comparison with earlier buyback or other capital-return exercises could not be confirmed from the cited announcement, which does not provide their historical percentages.

The separate 9.70% figure refers to the buyback amount as a percentage of paid-up equity share capital plus free reserves, not paid-up equity capital alone. ^[6]

The ₹215 buyback price is approximately 8.2% above Jyothy Labs’ latest implied market price, broadly in line with the three-month VWAP premium but below the premium to the price immediately before the announcement. However, a fully current P/E and P/B comparison cannot be confirmed because a complete TTM earnings denominator and book-equity/BVPS figure are not available in the cited material.

Buyback premium versus valuation

Using the exchange-reported market capitalisation of ₹7,296 Cr and 367,214,511 shares outstanding as of 6 November 2026, the implied market value per share is approximately ₹198.69. The ₹215 tender price therefore represents an implied premium of approximately 8.2%.

† Derived from the exchange-reported market capitalisation and share count; the market-capitalisation figure is rounded.

The buyback covers up to 68,37,210 shares, or approximately 1.86% of outstanding equity, for an offer size of ₹147 Cr ^[6]. Relative to the latest market capitalisation, the offer size is approximately 2.0% of equity value.

On valuation:

• FY26 PAT was reported at ₹333 Cr. Using that historical earnings base, the implied market-capitalisation P/E is approximately 21.9x; at the ₹215 tender price, the equivalent multiple would be approximately 23.7x. These are derived reference multiples, not current TTM multiples ^[7].
• Mechanically, the ₹215 price is 1.082 times the implied current price. Therefore, any valid current P/E or P/B at the market price would be approximately 8.2% higher at the buyback price, assuming the earnings and book-value denominators are unchanged.
• Current P/B could not be confirmed. The ₹1,515.90 Cr paid-up capital plus free-reserves figure in the buyback announcement is a standalone regulatory capital base used for determining the buyback limit, not a substitute for consolidated book equity or BVPS ^[4].
• The FY26 P/E should be treated cautiously: Q2 FY27 PAT fell 87.9% year on year to ₹10.6 Cr, reflecting severe margin pressure ^[8]. A complete current TTM P/E therefore requires the full latest earnings base.

Buyback versus dividends

Jyothy Labs’ buyback is a discretionary, selective capital return: shareholders may tender shares for cash, while non-tendering holders retain their shares and obtain a higher percentage ownership after the buyback. The company has also reserved the higher of the statutory entitlement or 15% of the buyback shares for small shareholders ^[6]. Promoters are excluded from the offer ^[9].

This differs from a dividend, which is generally a broader distribution to shareholders of record and does not reduce the share count. Jyothy Labs is therefore using a hybrid framework: management reportedly maintains a dividend policy of 35%-50% of profits, while FY26’s proposed dividend payout was reported at 38.6% of PAT ^{[10] [7]}. The buyback appears to be an additional return of surplus cash rather than a replacement for the ordinary dividend policy; the company explicitly cited surplus funds above operational and investment requirements as the rationale ^[6].

Peer disclosure

For the requested peer set, the cited FY26/FY27 material did not report a comparable dividend payout policy, distribution yield, or buyback programme:

Flair Writing Industries

• FY26/FY27 dividend payout policy: N/D — not disclosed
• FY26/FY27 buyback: N/D — not disclosed

Eveready Industries

• FY26/FY27 dividend payout policy: N/D — not disclosed
• FY26/FY27 buyback: N/D — not disclosed

DOMS Industries

• FY26/FY27 dividend payout policy: N/D — not disclosed
• FY26/FY27 buyback: N/D — not disclosed

Kokuyo Camlin

• FY26/FY27 dividend payout policy: N/D — not disclosed
• FY26/FY27 buyback: N/D — not disclosed

Linc

• FY26/FY27 dividend payout policy: N/D — not disclosed
• FY26/FY27 buyback: N/D — not disclosed

Accordingly, the defensible comparison is structural rather than quantitative: Jyothy Labs combines a stated recurring dividend framework with a one-off tender buyback priced at a premium, whereas a peer-by-peer ranking of dividend payout intensity cannot be established from the cited disclosures.